GenSight Biologics reported Aug. 31 that the Journal of Neuro-Ophthalmology (JNO) had published results from a long-term follow-up study of the gene therapy candidate Lumevoq that show sustained, bilateral treatment effect three years after a unilateral injection.The RESTORE study followed 61 patients with Leber hereditary optic neuropathy (LHON) due to a mutated ND4 mitochondrial gene.Paris-based GenSight said subjects in the …
Gene therapy start-up Vedere Bio II launches to treat blindness
The company, Vedere Bio II, launched with $77 million in series A financing to develop what it calls a “mutation agnostic optogenetics technology” to restore vision. As its name suggests, Vedere Bio II is a sequel to its predecessor company, Vedere Bio, which Novartis quietly acquired last year in a deal worth up to $280 million.
- Page 2 of 2
- 1
- 2